2021. Safety of Specifically Targeting Interleukin 13 with Tralokinumab in Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials. SKIN The Journal of Cutaneous Medicine. 5, 1 (Jan. 2021), s11. DOI:https://doi.org/10.25251/skin.5.supp.11.